ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11
Clinical trials for ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11 explained in plain language.
Never miss a new study
Get alerted when new ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11 trials appear
Sign up with your email to follow new studies for ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Matched conditions: ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13.1;Q22); CBFB-MYH11
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC